Phase II Iressa + Irradiation Followed by Chemo in NSCLC

Inclusion Criteria: * Signed informed consent. * 18 to 75 years inclusive. * At least one measurable lesions histologically confirmed inoperable stage III NSCLC. * WHO performance status of 0 to 2 inclusive. * Adequate pulmonary function, pulmonary dose volume histogram less than or equal to 40 %. * Life expectancy of at least 6 months. * Using secure contraceptives precautions. Exclusion Criteria: * Any previous anti cancer therapy for NSCLC. * Known severe hypersensitivity to these products * Any evidence of clinically active interstitial lung disease * Other co-existing malignancies, symptomatic metastases. * Abnormal blood test * Weight loss of over 15% in the 3 months before the start of the study. * Treatment with a non-approved or investigational drug within 30 days before Day 1 of study treatment.